Inify Laboratories: Continued strong growth – construction and establishment in the UK

Financial reports, Investor News 2025-04-30
STOCKHOLM – April 30, 2025 – Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, continued to deliver sales growth and positive margins in Sweden, alongside steady progress in its UK expansion. “We remain fully focused on growth in Sweden, our UK establishment, and further development of our system for gastrointestinal diagnostics,” […]
Read More

Inify Laboratories – Annual Report 2024

Annual reports, Financial reports, Investor News 2025-04-16
Stockholm – April 16, 2025 – Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, presents its Annual Report for the fiscal year ended December 31, 2024. The annual report is attached to this press release and is also available on the company’s website: www.inify.com. Printed copies of the report will be […]
Read More

Inify Laboratories – notice of Annual General Meeting on May 20, 2025

Annual General Meeting, Investor News 2025-04-16
Stockholm – April 16, 2025 – Inify Laboratories AB (publ), a unique laboratory service provider within pathology and cancer diagnostics, hereby invites its shareholders to Annual General Meeting on May 20, 2025. Please find attached the invitation including agenda and details on how to register and vote. The invitation is also available on the company’s […]
Read More

Panel talk about Inify’s fourth quarter 2024

Investor News 2025-02-28
Inify Laboratories continues to strengthen its position in the diagnostics market, achieving significant growth and expanding its reach. In Q4 2024, sales increased by 60% compared to the previous quarter and 472% compared to Q4 2023. By the end of the year, Inify held around 80% of the prostate diagnostics market in the Stockholm region […]
Read More

Inify Laboratories – New share capital registered

Investor News 2025-02-14
Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 12 February 2025 regarding the resolution to issue 30,202,366 new shares in a private placement (the "Private Placement Shares") and 3,464,300 new shares in a subsequent offering (the "Subsequent Offer Shares"). The share capital increase pertaining to the issuance […]
Read More